IL160231A0 - Adenosine a3 receptor agonists - Google Patents

Adenosine a3 receptor agonists

Info

Publication number
IL160231A0
IL160231A0 IL16023102A IL16023102A IL160231A0 IL 160231 A0 IL160231 A0 IL 160231A0 IL 16023102 A IL16023102 A IL 16023102A IL 16023102 A IL16023102 A IL 16023102A IL 160231 A0 IL160231 A0 IL 160231A0
Authority
IL
Israel
Prior art keywords
receptor agonists
adenosine
neutropennia
leukopenia
useful
Prior art date
Application number
IL16023102A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL160231A0 publication Critical patent/IL160231A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL16023102A 2001-08-08 2002-08-06 Adenosine a3 receptor agonists IL160231A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08
PCT/US2002/024696 WO2003014137A1 (en) 2001-08-08 2002-08-06 Adenosine a3 receptor agonists

Publications (1)

Publication Number Publication Date
IL160231A0 true IL160231A0 (en) 2004-07-25

Family

ID=23205248

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16023102A IL160231A0 (en) 2001-08-08 2002-08-06 Adenosine a3 receptor agonists
IL160231A IL160231A (en) 2001-08-08 2004-02-05 Adenosine a3 receptor agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160231A IL160231A (en) 2001-08-08 2004-02-05 Adenosine a3 receptor agonists

Country Status (20)

Country Link
US (1) US20030078232A1 (da)
EP (1) EP1414837B1 (da)
JP (1) JP4357960B2 (da)
KR (1) KR100923888B1 (da)
CN (1) CN1244589C (da)
AT (1) ATE307136T1 (da)
AU (1) AU2002327426C1 (da)
CA (1) CA2456744A1 (da)
DE (1) DE60206775T2 (da)
DK (1) DK1414837T3 (da)
ES (1) ES2247371T3 (da)
HU (1) HUP0401437A3 (da)
IL (2) IL160231A0 (da)
MX (1) MXPA04001185A (da)
NO (1) NO327997B1 (da)
NZ (1) NZ530976A (da)
PL (1) PL368205A1 (da)
RU (1) RU2298557C2 (da)
WO (1) WO2003014137A1 (da)
ZA (1) ZA200401000B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
WO2003029264A2 (en) * 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US6914053B2 (en) * 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CA2585581A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
WO2006125211A1 (en) * 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
ES2358351T3 (es) * 2005-10-13 2011-05-09 Cv Therapeutics, Inc. Agonistas del receptor de adenosina a1.
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
WO2008116911A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
NZ579248A (en) * 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CA2702644A1 (en) * 2007-10-16 2009-04-23 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
IN2014DN11027A (da) 2012-06-26 2015-09-25 Aniona Aps
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2018212980A1 (en) * 2017-05-19 2018-11-22 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
WO2020253866A1 (zh) * 2019-06-21 2020-12-24 中国人民解放军军事科学院军事医学研究院 腺苷类化合物、其可药用盐或其立体异构体及用途
JP2024502068A (ja) * 2020-12-29 2024-01-17 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド Ａ３アデノシン受容体アゴニスト及びその調製方法と用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists

Also Published As

Publication number Publication date
MXPA04001185A (es) 2005-06-17
ATE307136T1 (de) 2005-11-15
ZA200401000B (en) 2004-10-18
PL368205A1 (en) 2005-03-21
CA2456744A1 (en) 2003-02-20
DE60206775T2 (de) 2006-07-20
NO327997B1 (no) 2009-11-09
KR100923888B1 (ko) 2009-10-28
AU2002327426B2 (en) 2007-06-14
CN1244589C (zh) 2006-03-08
KR20040023733A (ko) 2004-03-18
US20030078232A1 (en) 2003-04-24
NZ530976A (en) 2005-07-29
CN1538972A (zh) 2004-10-20
AU2002327426A2 (en) 2003-02-24
WO2003014137A1 (en) 2003-02-20
EP1414837B1 (en) 2005-10-19
DK1414837T3 (da) 2005-11-07
DE60206775D1 (de) 2006-03-02
RU2298557C2 (ru) 2007-05-10
ES2247371T3 (es) 2006-03-01
HUP0401437A2 (hu) 2004-11-29
AU2002327426C1 (en) 2008-03-06
NO20040969L (no) 2004-04-19
JP2005501842A (ja) 2005-01-20
IL160231A (en) 2010-11-30
RU2004106635A (ru) 2005-07-27
HUP0401437A3 (en) 2007-05-29
EP1414837A1 (en) 2004-05-06
JP4357960B2 (ja) 2009-11-04

Similar Documents

Publication Publication Date Title
IL160231A (en) Adenosine a3 receptor agonists
MXPA04001524A (es) 29-enoles de rapamicina.
AP2002002458A0 (en) Compounds for the treatment of ischemia.
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
HK1062911A1 (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
PT1459751E (pt) (s,s)-reboxetina para tratar as enxaquecas
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
DZ3168A1 (fr) Dérivés de purine.
SI1699795T1 (sl) Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
HK1052940A1 (en) Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
NO2010004I1 (no) 0,02 mg etinylostradiol (som betadexclathrat) og 3mg drospirenon
AU2002223084A1 (en) Nitrogen substituted 1,2,4-triazolo(3,4-a)phthalazine derivatives for enhancing cognition
EP1185276A4 (en) ISOPHOSPHORAMIDE MUSTARD GAS ANALOGS AND THEIR USE
WO2004022573A3 (en) Adenosine a3 receptor agonists
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
WO2003039484A3 (en) Novel compositions and methods for cancer
DK1223930T3 (da) Behandling af dyskinesi
WO1999043285A3 (en) Sulphonamide derivatives
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES